Table 1.

Cell line characteristics

Line	Species	Strain/genotype	Growth	Drug sensitivity	Time to G/A 0.25	Median OS from G/A 0.25	Tnfrsf17 RMA	Modifications
Vk12598	C57BL/6	Vk*MYC	E-MM	Cy	5 weeks	10 days	50	n.a.
Vk27181	C57BL/6	Vk*MYCDLox	E-MM	Cy, Bor	7 weeks	20 days	29	n.a.
Vk29790	C57BL/6	Vk*MYCDLox × hC123 × mCRBNhet	MM	Cy, Pom	14 weeks	99 days	54	n.a.
Vk32908	C57BL/6	Vk*MYC × hC123 × mCRBNnull	E-MM	Cy, Pom	4 weeks	19 days	208	n.a.
Vk14750VITRO	C57BL/6	Vk*MYC	VITRO	Pom	n.a.	n.a.	29	pWPI-hCRBN
Vk32245VITRO	C57BL/6	Vk*MYC	VITRO	Pom	n.a.	n.a.	150	pWPI-hCRBN
J558	Balb/c	WT	VITRO	n.d.	n.a.	n.a.	n.a.	pWPI-mBCMA
H929	Human	WT	VITRO	n.d.	n.a.	n.a.	1,477	n.a.

Note: The genotype and sensitivity to drugs of the cell lines used in this study are reported. MM, E-MM, and VITRO indicate growth restricted to the BM, extramedullary dissemination, or growth in vitro, respectively. For transplantable lines, the time to engraftment, measured as the number of weeks required after transplantation for the M-spike to reach a G/A ratio = 0.25, indicative of an M-spike = 7 g/L, is reported, as well as the median survival, in days, following the detection of a G/A = 0.25. RMA-summarized Tnfrsf17 transcript expression is indicated. For cell lines grown in vitro, the transduced genes are listed.

Abbreviations: Bor, bortezomib; MM, multiple myeloma; n.a., not available; n.d., not detected; OS, overall survival; RMA, robust multi-array average.